Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo
The present study was conducted to investigate the functional implication of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC(1)) receptor in the adrenal catecholamine (CA) secretion induced by either PACAP-27 or vasoactive intestinal polypeptide (VIP) in anesthetized dogs....
Gespeichert in:
| Veröffentlicht in: | American journal of physiology. Regulatory, integrative and comparative physiology integrative and comparative physiology, 2001-02, Vol.280 (2), p.R510-R518 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | R518 |
|---|---|
| container_issue | 2 |
| container_start_page | R510 |
| container_title | American journal of physiology. Regulatory, integrative and comparative physiology |
| container_volume | 280 |
| creator | Lamouche, S Yamaguchi, N |
| description | The present study was conducted to investigate the functional implication of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC(1)) receptor in the adrenal catecholamine (CA) secretion induced by either PACAP-27 or vasoactive intestinal polypeptide (VIP) in anesthetized dogs. PACAP-27, VIP, and their respective antagonists were locally infused to the left adrenal gland via the left adrenolumbar artery. Plasma CA concentrations in adrenal venous and aortic blood were determined by means of a high-performance liquid chromatograph coupled with an electrochemical detector. Adrenal venous blood flow was measured by gravimetry. The administration of PACAP-27 (50 ng) resulted in a significant increase in adrenal CA output. VIP (5 microg) also increased the basal CA secretion to an extent comparable to that observed with PACAP-27. In the presence of PACAP partial sequence 6--27 [PACAP-(6--27); a PAC(1) receptor antagonist] at the doses of 7.5 and 15 microg, the CA response to PACAP-27 was attenuated by approximately 50 and approximately 95%, respectively. Although the CA secretagogue effect of VIP was blocked by approximately 85% in the presence of PACAP-(6--27) (15 microg), it remained unaffected by VIP partial sequence 10--28 [VIP-(10--28); a VIP receptor antagonist] at the dose of 15 microg. Furthermore, the CA response to PACAP-27 did not change in the presence of the same dose of VIP--(10--28). The results indicate that PACAP-(6--27) diminished, in a dose-dependent manner, the increase in adrenal CA secretion induced by PACAP-27. The results also indicate that the CA response to either PACAP-27 or VIP was selectively inhibited by PACAP-(6--27) but not by VIP-(10--28). It is concluded that PAC(1) receptor is primarily involved in the CA secretion induced by both PACAP-27 and VIP in the canine adrenal medulla in vivo. |
| doi_str_mv | 10.1152/ajpregu.2001.280.2.R510 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76970070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76970070</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-ada56d9b54847d9fbd862f92a9fbb5cf946599090f4e8f7c1606a34adcda5953</originalsourceid><addsrcrecordid>eNo1kD1PwzAURT2AaCn8BfCEYEh4tmMnHquKj0qVqKqKhSFy7BdIlcbBSSr13xNEme4dzrnDJeSWQcyY5I9m1wb8HGIOwGKeQczjjWRwRqYglIgUY3pCLrtuBwCJSMQFmTDGIZMZn5KPja-R-pKu54t79kADWmx7H2jVUOMCNqam1vRov3xt9lWDtEMbsK98MyJusOhocfy152tqGkffl-tf91Ad_BU5L03d4fUpZ2T7_LRdvEart5flYr6KWiZ0HxlnpHK6kEmWpE6XhcsULzU3Yy2kLXWipNagoUwwK1PLFCgjEuPsKGopZuTub7YN_nvArs_3VWexrk2DfujyVOkUIIURvDmBQ7FHl7eh2ptwzP_fED_cZGEa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76970070</pqid></control><display><type>article</type><title>Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo</title><source>MEDLINE</source><source>American Physiological Society</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lamouche, S ; Yamaguchi, N</creator><creatorcontrib>Lamouche, S ; Yamaguchi, N</creatorcontrib><description>The present study was conducted to investigate the functional implication of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC(1)) receptor in the adrenal catecholamine (CA) secretion induced by either PACAP-27 or vasoactive intestinal polypeptide (VIP) in anesthetized dogs. PACAP-27, VIP, and their respective antagonists were locally infused to the left adrenal gland via the left adrenolumbar artery. Plasma CA concentrations in adrenal venous and aortic blood were determined by means of a high-performance liquid chromatograph coupled with an electrochemical detector. Adrenal venous blood flow was measured by gravimetry. The administration of PACAP-27 (50 ng) resulted in a significant increase in adrenal CA output. VIP (5 microg) also increased the basal CA secretion to an extent comparable to that observed with PACAP-27. In the presence of PACAP partial sequence 6--27 [PACAP-(6--27); a PAC(1) receptor antagonist] at the doses of 7.5 and 15 microg, the CA response to PACAP-27 was attenuated by approximately 50 and approximately 95%, respectively. Although the CA secretagogue effect of VIP was blocked by approximately 85% in the presence of PACAP-(6--27) (15 microg), it remained unaffected by VIP partial sequence 10--28 [VIP-(10--28); a VIP receptor antagonist] at the dose of 15 microg. Furthermore, the CA response to PACAP-27 did not change in the presence of the same dose of VIP--(10--28). The results indicate that PACAP-(6--27) diminished, in a dose-dependent manner, the increase in adrenal CA secretion induced by PACAP-27. The results also indicate that the CA response to either PACAP-27 or VIP was selectively inhibited by PACAP-(6--27) but not by VIP-(10--28). It is concluded that PAC(1) receptor is primarily involved in the CA secretion induced by both PACAP-27 and VIP in the canine adrenal medulla in vivo.</description><identifier>ISSN: 0363-6119</identifier><identifier>DOI: 10.1152/ajpregu.2001.280.2.R510</identifier><identifier>PMID: 11208582</identifier><language>eng</language><publisher>United States</publisher><subject>Adrenal Medulla - blood supply ; Adrenal Medulla - drug effects ; Adrenal Medulla - physiology ; Animals ; Arteries ; Blood Pressure - drug effects ; Dogs ; Epinephrine - blood ; Epinephrine - secretion ; Heart Rate - drug effects ; Infusions, Intra-Arterial ; Neuropeptides - administration & dosage ; Neuropeptides - pharmacology ; Neurotransmitter Agents - pharmacology ; Norepinephrine - blood ; Norepinephrine - secretion ; Peptide Fragments - pharmacology ; Pituitary Adenylate Cyclase-Activating Polypeptide ; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide ; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I ; Receptors, Pituitary Hormone - drug effects ; Receptors, Pituitary Hormone - physiology ; Regional Blood Flow - drug effects ; Vasoactive Intestinal Peptide - administration & dosage ; Vasoactive Intestinal Peptide - pharmacology</subject><ispartof>American journal of physiology. Regulatory, integrative and comparative physiology, 2001-02, Vol.280 (2), p.R510-R518</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11208582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamouche, S</creatorcontrib><creatorcontrib>Yamaguchi, N</creatorcontrib><title>Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo</title><title>American journal of physiology. Regulatory, integrative and comparative physiology</title><addtitle>Am J Physiol Regul Integr Comp Physiol</addtitle><description>The present study was conducted to investigate the functional implication of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC(1)) receptor in the adrenal catecholamine (CA) secretion induced by either PACAP-27 or vasoactive intestinal polypeptide (VIP) in anesthetized dogs. PACAP-27, VIP, and their respective antagonists were locally infused to the left adrenal gland via the left adrenolumbar artery. Plasma CA concentrations in adrenal venous and aortic blood were determined by means of a high-performance liquid chromatograph coupled with an electrochemical detector. Adrenal venous blood flow was measured by gravimetry. The administration of PACAP-27 (50 ng) resulted in a significant increase in adrenal CA output. VIP (5 microg) also increased the basal CA secretion to an extent comparable to that observed with PACAP-27. In the presence of PACAP partial sequence 6--27 [PACAP-(6--27); a PAC(1) receptor antagonist] at the doses of 7.5 and 15 microg, the CA response to PACAP-27 was attenuated by approximately 50 and approximately 95%, respectively. Although the CA secretagogue effect of VIP was blocked by approximately 85% in the presence of PACAP-(6--27) (15 microg), it remained unaffected by VIP partial sequence 10--28 [VIP-(10--28); a VIP receptor antagonist] at the dose of 15 microg. Furthermore, the CA response to PACAP-27 did not change in the presence of the same dose of VIP--(10--28). The results indicate that PACAP-(6--27) diminished, in a dose-dependent manner, the increase in adrenal CA secretion induced by PACAP-27. The results also indicate that the CA response to either PACAP-27 or VIP was selectively inhibited by PACAP-(6--27) but not by VIP-(10--28). It is concluded that PAC(1) receptor is primarily involved in the CA secretion induced by both PACAP-27 and VIP in the canine adrenal medulla in vivo.</description><subject>Adrenal Medulla - blood supply</subject><subject>Adrenal Medulla - drug effects</subject><subject>Adrenal Medulla - physiology</subject><subject>Animals</subject><subject>Arteries</subject><subject>Blood Pressure - drug effects</subject><subject>Dogs</subject><subject>Epinephrine - blood</subject><subject>Epinephrine - secretion</subject><subject>Heart Rate - drug effects</subject><subject>Infusions, Intra-Arterial</subject><subject>Neuropeptides - administration & dosage</subject><subject>Neuropeptides - pharmacology</subject><subject>Neurotransmitter Agents - pharmacology</subject><subject>Norepinephrine - blood</subject><subject>Norepinephrine - secretion</subject><subject>Peptide Fragments - pharmacology</subject><subject>Pituitary Adenylate Cyclase-Activating Polypeptide</subject><subject>Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide</subject><subject>Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</subject><subject>Receptors, Pituitary Hormone - drug effects</subject><subject>Receptors, Pituitary Hormone - physiology</subject><subject>Regional Blood Flow - drug effects</subject><subject>Vasoactive Intestinal Peptide - administration & dosage</subject><subject>Vasoactive Intestinal Peptide - pharmacology</subject><issn>0363-6119</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kD1PwzAURT2AaCn8BfCEYEh4tmMnHquKj0qVqKqKhSFy7BdIlcbBSSr13xNEme4dzrnDJeSWQcyY5I9m1wb8HGIOwGKeQczjjWRwRqYglIgUY3pCLrtuBwCJSMQFmTDGIZMZn5KPja-R-pKu54t79kADWmx7H2jVUOMCNqam1vRov3xt9lWDtEMbsK98MyJusOhocfy152tqGkffl-tf91Ad_BU5L03d4fUpZ2T7_LRdvEart5flYr6KWiZ0HxlnpHK6kEmWpE6XhcsULzU3Yy2kLXWipNagoUwwK1PLFCgjEuPsKGopZuTub7YN_nvArs_3VWexrk2DfujyVOkUIIURvDmBQ7FHl7eh2ptwzP_fED_cZGEa</recordid><startdate>200102</startdate><enddate>200102</enddate><creator>Lamouche, S</creator><creator>Yamaguchi, N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200102</creationdate><title>Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo</title><author>Lamouche, S ; Yamaguchi, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-ada56d9b54847d9fbd862f92a9fbb5cf946599090f4e8f7c1606a34adcda5953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adrenal Medulla - blood supply</topic><topic>Adrenal Medulla - drug effects</topic><topic>Adrenal Medulla - physiology</topic><topic>Animals</topic><topic>Arteries</topic><topic>Blood Pressure - drug effects</topic><topic>Dogs</topic><topic>Epinephrine - blood</topic><topic>Epinephrine - secretion</topic><topic>Heart Rate - drug effects</topic><topic>Infusions, Intra-Arterial</topic><topic>Neuropeptides - administration & dosage</topic><topic>Neuropeptides - pharmacology</topic><topic>Neurotransmitter Agents - pharmacology</topic><topic>Norepinephrine - blood</topic><topic>Norepinephrine - secretion</topic><topic>Peptide Fragments - pharmacology</topic><topic>Pituitary Adenylate Cyclase-Activating Polypeptide</topic><topic>Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide</topic><topic>Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</topic><topic>Receptors, Pituitary Hormone - drug effects</topic><topic>Receptors, Pituitary Hormone - physiology</topic><topic>Regional Blood Flow - drug effects</topic><topic>Vasoactive Intestinal Peptide - administration & dosage</topic><topic>Vasoactive Intestinal Peptide - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamouche, S</creatorcontrib><creatorcontrib>Yamaguchi, N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of physiology. Regulatory, integrative and comparative physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamouche, S</au><au>Yamaguchi, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo</atitle><jtitle>American journal of physiology. Regulatory, integrative and comparative physiology</jtitle><addtitle>Am J Physiol Regul Integr Comp Physiol</addtitle><date>2001-02</date><risdate>2001</risdate><volume>280</volume><issue>2</issue><spage>R510</spage><epage>R518</epage><pages>R510-R518</pages><issn>0363-6119</issn><abstract>The present study was conducted to investigate the functional implication of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC(1)) receptor in the adrenal catecholamine (CA) secretion induced by either PACAP-27 or vasoactive intestinal polypeptide (VIP) in anesthetized dogs. PACAP-27, VIP, and their respective antagonists were locally infused to the left adrenal gland via the left adrenolumbar artery. Plasma CA concentrations in adrenal venous and aortic blood were determined by means of a high-performance liquid chromatograph coupled with an electrochemical detector. Adrenal venous blood flow was measured by gravimetry. The administration of PACAP-27 (50 ng) resulted in a significant increase in adrenal CA output. VIP (5 microg) also increased the basal CA secretion to an extent comparable to that observed with PACAP-27. In the presence of PACAP partial sequence 6--27 [PACAP-(6--27); a PAC(1) receptor antagonist] at the doses of 7.5 and 15 microg, the CA response to PACAP-27 was attenuated by approximately 50 and approximately 95%, respectively. Although the CA secretagogue effect of VIP was blocked by approximately 85% in the presence of PACAP-(6--27) (15 microg), it remained unaffected by VIP partial sequence 10--28 [VIP-(10--28); a VIP receptor antagonist] at the dose of 15 microg. Furthermore, the CA response to PACAP-27 did not change in the presence of the same dose of VIP--(10--28). The results indicate that PACAP-(6--27) diminished, in a dose-dependent manner, the increase in adrenal CA secretion induced by PACAP-27. The results also indicate that the CA response to either PACAP-27 or VIP was selectively inhibited by PACAP-(6--27) but not by VIP-(10--28). It is concluded that PAC(1) receptor is primarily involved in the CA secretion induced by both PACAP-27 and VIP in the canine adrenal medulla in vivo.</abstract><cop>United States</cop><pmid>11208582</pmid><doi>10.1152/ajpregu.2001.280.2.R510</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-6119 |
| ispartof | American journal of physiology. Regulatory, integrative and comparative physiology, 2001-02, Vol.280 (2), p.R510-R518 |
| issn | 0363-6119 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76970070 |
| source | MEDLINE; American Physiological Society; EZB-FREE-00999 freely available EZB journals |
| subjects | Adrenal Medulla - blood supply Adrenal Medulla - drug effects Adrenal Medulla - physiology Animals Arteries Blood Pressure - drug effects Dogs Epinephrine - blood Epinephrine - secretion Heart Rate - drug effects Infusions, Intra-Arterial Neuropeptides - administration & dosage Neuropeptides - pharmacology Neurotransmitter Agents - pharmacology Norepinephrine - blood Norepinephrine - secretion Peptide Fragments - pharmacology Pituitary Adenylate Cyclase-Activating Polypeptide Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I Receptors, Pituitary Hormone - drug effects Receptors, Pituitary Hormone - physiology Regional Blood Flow - drug effects Vasoactive Intestinal Peptide - administration & dosage Vasoactive Intestinal Peptide - pharmacology |
| title | Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T06%3A27%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20PAC(1)%20receptor%20in%20adrenal%20catecholamine%20secretion%20induced%20by%20PACAP%20and%20VIP%20in%20vivo&rft.jtitle=American%20journal%20of%20physiology.%20Regulatory,%20integrative%20and%20comparative%20physiology&rft.au=Lamouche,%20S&rft.date=2001-02&rft.volume=280&rft.issue=2&rft.spage=R510&rft.epage=R518&rft.pages=R510-R518&rft.issn=0363-6119&rft_id=info:doi/10.1152/ajpregu.2001.280.2.R510&rft_dat=%3Cproquest_pubme%3E76970070%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76970070&rft_id=info:pmid/11208582&rfr_iscdi=true |